|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2005
Bronchodilator response in the lung health study over 11 yrs
1 University of Manitoba, Winnipeg, Manitoba, Canada. 2 University of Minnesota, Minneapolis, MN, 3 University of California, Los Angeles, CA, 4 University of Utah, Salt Lake City, UT, and 5 Mayo Clinic, Rochester, MN, USA.
CORRESPONDENCE: N. R. Anthonisen, Respiratory Hospital, 810 Sherbrook St, Winnipeg MB, R3A 1R8, Canada. Fax: 1 2047871220. E-mail: nanthonisen@exchange.hsc.mb.ca
Keywords: Forced expiratory volume in one second, methacholine reactivity, smoking
Received: September 1, 2004
Accepted March 17, 2005
Long-term changes in bronchodilator response in people with mild chronic obstructive pulmonary disease were assessed in this study.
Changes in forced expiratory volume in one second (FEV1) in response to isoproterenol was measured in 4,194 participants in the Lung Health Study annually for 5 yrs, and again 11 yrs after study entry. Responses were quantitated in terms of mL (absolute), as per cent of the pre-bronchodilator value (relative), and as a per cent of the predicted normal value (% predicted).
At baseline, the mean pre-bronchodilator FEV1 was 75.4% predicted, and responses were small. Relative and percentage predicted responses were similar in males and females; and correlated positively with methacholine reactivity, and negatively with smoking intensity and age. Baseline bronchodilator responses did not correlate with subsequent decline in FEV1. There was a substantial increase in response over the first year of the study, largely due to smoking cessation, with larger increases in those who stopped smoking. After the first year absolute responses changed little in those who maintained smoking cessation, but increased in those who did not. Mean relative and percentage predicted responses increased in all participants throughout the study. There was substantial annual variability of absolute response, and it was poorly reproducible in individual participants.
In conclusion, smoking cessation increased bronchodilator response, and response did not predict the rate of decline of forced expiratory volume in one second.
This article has been cited by other articles:
|
|
 |
|
  R. L. Dellaca, P. P. Pompilio, P. P. Walker, N. Duffy, A. Pedotti, and P. M. A. Calverley Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD Eur. Respir. J., June 1, 2009; 33(6): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cazzola From large clinical trials to management of COPD in the real world Therapeutic Advances in Respiratory Disease, February 1, 2009; 3(1): 39 - 46. [Abstract] [PDF]
|
|
|
|
|
|
R. Dal Negro, M. Visconti, F. Trevisan, S. Bertacco, C. Micheletto, and S. Tognella Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 271 - 277. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Kainu, A. Lindqvist, S. Sarna, B. Lundback, and A. Sovijarvi FEV1 Response to Bronchodilation in an Adult Urban Population Chest, August 1, 2008; 134(2): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Mannino Coexisting Asthma and COPD: Confused Clinicians or Poor Prognosticator? Chest, July 1, 2008; 134(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Han, D. Postma, D. M. Mannino, N. D. Giardino, S. Buist, J. L. Curtis, and F. J. Martinez Gender and Chronic Obstructive Pulmonary Disease: Why It Matters Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1179 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hizawa, H. Makita, Y. Nasuhara, T. Betsuyaku, Y. Itoh, K. Nagai, M. Hasegawa, and M. Nishimura {beta}2-Adrenergic Receptor Genetic Polymorphisms and Short-term Bronchodilator Responses in Patients With COPD Chest, November 1, 2007; 132(5): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Makita, Y. Nasuhara, K. Nagai, Y. Ito, M. Hasegawa, T. Betsuyaku, Y. Onodera, N. Hizawa, M. Nishimura, and the Hokkaido COPD Cohort Study Group Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease Thorax, November 1, 2007; 62(11): 932 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Johannessen, S. Lehmann, E. R. Omenaas, G. E. Eide, P. S. Bakke, and A. Gulsvik Post-Bronchodilator Spirometry Reference Values in Adults and Implications for Disease Management Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1316 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. M. Wouters Approaches to Improving Health Status in Chronic Obstructive Pulmonary Disease: One or Several? Proceedings of the ATS, May 1, 2006; 3(3): 262 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Ind COPD disease progression and airway inflammation: uncoupled by smoking cessation Eur. Respir. J., November 1, 2005; 26(5): 764 - 766. [Full Text] [PDF]
|
|
|
|
|
|
E. F. Hansen and J. Vestbo Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness? Eur. Respir. J., July 1, 2005; 26(1): 6 - 7. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |